Search - tctmd.com

Displaying 1 - 20 of 59

Sort: Relevancy | Date

Presentation ESC 2024

Optical coherence tomography-guided coronary intervention in patients with complex lesions: The OCCUPI Randomized Clinical Trial

Presenter: Byeong-Keuk Kim

September 02, 2024

Presentation ESC 2024

The ASSURE DES Randomized Clinical Trial

Presenter: Jung-Min Ahn

August 31, 2024

Presentation EuroPCR 2023

BIOADAPTOR RCT: Randomized Controlled Trial of Sirolimus-Eluting Bioadaptor Scaffold Versus Zotarolimus-Eluting Drug-Eluting Stent

Presenter: Shigeru Saito

May 18, 2023

Presentation JIM 2020

Drug-coated balloon vs. drug eluting stent for small coronary vessel disease: 6-mo. primary outcome of the PICCOLETO II randomized clinical trial.

Presenter: Bernardo Cortese

February 13, 2020

Presentation Cardiovascular Interventions 2018

Show me the Data: Key Clinical Trials of 2018

Presenter: Ehtisham Mahmud

October 26, 2018

Presentation CIT 2018

A First-in-Man Study of the Firesorb Sirolimus Target Eluting Bioresorbable Vascular Scaffold in Patients with Coronary Artery Disease (FUTURE-I): Two-Year Clinical and Imaging Outcomes

Presenter: Bo Xu

March 23, 2018

Presentation JIM 2017

Perspectives on the ABSORB Randomized Trials: Take-home Messages for the Clinical Practitioner

Presenter: Gregg W. Stone

February 08, 2017

Presentation TCT 2016

NOBLE: A Prospective, Randomized Trial Comparing Biolimus-Eluting Stents and Bypass Graft Surgery in Selected Patients With Left Main Coronary Artery Disease

Presenter: Martin B. Leon, Keith G. Oldroyd, Evald H. Christiansen

October 31, 2016

Presentation TCT 2016

EXCEL: A Prospective, Randomized Trial Comparing Everolimus-Eluting Stents and Bypass Graft Surgery in Selected Patients With Left Main Coronary Artery Disease

Presenter: Martin B. Leon, Keith G. Oldroyd, Gregg W. Stone

October 31, 2016

Presentation TCT 2016

LEADERS FREE: Two-Year Clinical and Subgroup Outcomes From a Prospective, Randomized Trial of a Polymer-Free Drug-Coated Stent and a Bare Metal Stent in Patients With Coronary Artery Disease at High Bleeding Risk

Presenter: David W.M. Muller, Jonathan M. Hill, Philip M. Urban

October 30, 2016

Presentation TCT 2016

ABSORB II: Three-Year Clinical Outcomes From a Prospective, Randomized Trial of an Everolimus-Eluting Bioresorbable Vascular Scaffold vs an Everolimus-Eluting Metallic Stent in Patients With Coronary Artery Disease

Presenter: David W.M. Muller, Jonathan M. Hill, Patrick W. Serruys

October 30, 2016

Presentation TCT 2016

ABSORB China: Two-Year Clinical Outcomes From a Prospective, Randomized Trial of an Everolimus-Eluting Bioresorbable Vascular Scaffold vs an Everolimus-Eluting Metallic Stent in Patients With Coronary Artery Disease

Presenter: David W.M. Muller, Jonathan M. Hill, Runlin Gao

October 30, 2016

Presentation TCT 2016

BIONICS: A Prospective, Randomized Trial of a Ridaforolimus-Eluting Coronary Stent vs a Zotarolimus-Eluting Stent in a More-Comers Population of Patients With Coronary Artery Disease

Presenter: Gregg W. Stone, Wayne B. Batchelor, David E. Kandzari

October 30, 2016

Presentation TCT 2016

BIO-RESORT (TWENTE III): A Prospective, Randomized Three-Arm Trial Comparing Two Different Biodegradable Polymer-Based Drug-Eluting Stents and a Durable Polymer-Based Drug-Eluting Stent in an All-Comers Population of Patients With Coronary Artery Disease

Presenter: Gregg W. Stone, Wayne B. Batchelor, Clemens von Birgelen

October 30, 2016

Presentation JIM 2016

Fantom®Differentiating Features and Clinical Trial Insights

Presenter: Alexandre Abizaid

February 09, 2016

Presentation

TCT 2015 Late Breaking Trials: LEADERS FREE and RESPECT LATE

Presenter: Gregg W. Stone

November 23, 2015

Presentation ESC 2015

12-month clinical and 13-month angiographic outcomes from a randomized trial evaluating the Absorb Bioresorbable Vascular Scaffold vs_ metallic DES in de novo native coronary artery lesions

Presenter: Takeshi Kimura

September 01, 2015

Presentation

Trial of a Paclitaxel-Coated Balloon for Femoropopliteal Artery Disease

Presenter: Kenneth Rosenfield

June 25, 2015

Presentation EuroPCR 2015

Five-Year Follow-up of Safety and Efficacy of the Resolute Zotarolimus-Eluting Stent: Insights from the RESOLUTE Global Clinical Trial Program in Approximately 8000 Patients

Presenter: Sigmund Silber

May 19, 2015

Presentation

Antiplatelet Therapy Duration Following BMS or DES: The DAPT Randomized Clinical Trial

Presenter: D. J. Kereiakes

March 24, 2015

Advertisement

Optical coherence tomography-guided coronary intervention in patients with complex lesions: The OCCUPI Randomized Clinical Trial

The ASSURE DES Randomized Clinical Trial

BIOADAPTOR RCT: Randomized Controlled Trial of Sirolimus-Eluting Bioadaptor Scaffold Versus Zotarolimus-Eluting Drug-Eluting Stent

Drug-coated balloon vs. drug eluting stent for small coronary vessel disease: 6-mo. primary outcome of the PICCOLETO II randomized clinical trial.

Show me the Data: Key Clinical Trials of 2018

A First-in-Man Study of the Firesorb Sirolimus Target Eluting Bioresorbable Vascular Scaffold in Patients with Coronary Artery Disease (FUTURE-I): Two-Year Clinical and Imaging Outcomes

Perspectives on the ABSORB Randomized Trials: Take-home Messages for the Clinical Practitioner

NOBLE: A Prospective, Randomized Trial Comparing Biolimus-Eluting Stents and Bypass Graft Surgery in Selected Patients With Left Main Coronary Artery Disease

EXCEL: A Prospective, Randomized Trial Comparing Everolimus-Eluting Stents and Bypass Graft Surgery in Selected Patients With Left Main Coronary Artery Disease

LEADERS FREE: Two-Year Clinical and Subgroup Outcomes From a Prospective, Randomized Trial of a Polymer-Free Drug-Coated Stent and a Bare Metal Stent in Patients With Coronary Artery Disease at High Bleeding Risk

ABSORB II: Three-Year Clinical Outcomes From a Prospective, Randomized Trial of an Everolimus-Eluting Bioresorbable Vascular Scaffold vs an Everolimus-Eluting Metallic Stent in Patients With Coronary Artery Disease

ABSORB China: Two-Year Clinical Outcomes From a Prospective, Randomized Trial of an Everolimus-Eluting Bioresorbable Vascular Scaffold vs an Everolimus-Eluting Metallic Stent in Patients With Coronary Artery Disease

BIONICS: A Prospective, Randomized Trial of a Ridaforolimus-Eluting Coronary Stent vs a Zotarolimus-Eluting Stent in a More-Comers Population of Patients With Coronary Artery Disease

BIO-RESORT (TWENTE III): A Prospective, Randomized Three-Arm Trial Comparing Two Different Biodegradable Polymer-Based Drug-Eluting Stents and a Durable Polymer-Based Drug-Eluting Stent in an All-Comers Population of Patients With Coronary Artery Disease

Fantom®Differentiating Features and Clinical Trial Insights

TCT 2015 Late Breaking Trials: LEADERS FREE and RESPECT LATE

12-month clinical and 13-month angiographic outcomes from a randomized trial evaluating the Absorb Bioresorbable Vascular Scaffold vs_ metallic DES in de novo native coronary artery lesions

Trial of a Paclitaxel-Coated Balloon for Femoropopliteal Artery Disease

Five-Year Follow-up of Safety and Efficacy of the Resolute Zotarolimus-Eluting Stent: Insights from the RESOLUTE Global Clinical Trial Program in Approximately 8000 Patients

Antiplatelet Therapy Duration Following BMS or DES: The DAPT Randomized Clinical Trial

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content